US2008269107A1PendingUtilityA1

Methods and Compositions for Treatment of Cancers with Hoxb4

17
Individually held — no corporate assignee on recordPriority: Oct 21, 2005Filed: Oct 23, 2006Published: Oct 30, 2008
Est. expiryOct 21, 2025(expired)· nominal 20-yr term from priority
Inventors:Kamal K. Mubarak
A61P 35/00A61K 38/00A61K 48/00C07K 14/4705
17
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

In some embodiments, without limitation, the invention comprises methods and compositions for the treatment of mammalian cancers, comprising the administration of HOXB4 protein and/or the overexpression of HOXB4 nucleotide sequence in order to induce apoptosis or otherwise decrease the survival of the target cancer cells.

Claims

exact text as granted — not AI-modified
1 . A method of decreasing the survival of cancer cells in a mammal, comprising the step of administering to the mammal a compound comprising HOXB4 protein in a therapeutically effective amount that decreases the survival of at least some of the cancer cells. 
     
     
         2 . The method of  claim 1 , wherein the mammal is a human. 
     
     
         3 . The method of  claim 1  or  claim 2 , wherein the HOXB4 protein comprises a polypeptide of all or part of SEQ ID NO. 1. 
     
     
         4 . A method of inducing apoptosis in cancer cells in a mammal, comprising the step of administering to the mammal a compound comprising HOXB4 protein in a therapeutically effective amount that induces apoptosis in at least some of the cancer cells. 
     
     
         5 . The method of  claim 4 , wherein the mammal is a human. 
     
     
         6 . The method of  claim 4  or  claim 5 , wherein the HOXB4 protein comprises a polypeptide of all or part of SEQ ID NO. 1. 
     
     
         7 . A method of decreasing the survival of cancer cells in a mammal, comprising the step of transfecting the mammal with a HOXB4 nucleotide sequence in a therapeutically effective amount that decreases the survival of at least some of the cancer cells. 
     
     
         8 . The method of  claim 7 , wherein the mammal is a human. 
     
     
         9 . The method of  claim 7  or  claim 8 , wherein the HOXB4 nucleotide sequence comprises all or part of SEQ ID NO. 2. 
     
     
         10 . A method of inducing apoptosis in cancer cells in a mammal, comprising the step of transfecting the mammal with a HOXB4 nucleotide sequence in a therapeutically effective amount that induces apoptosis in at least some of the cancer cells. 
     
     
         11 . The method of  claim 11 , wherein the mammal is a human. 
     
     
         12 . The method of  claim 11  or  claim 12 , wherein the HOXB4 nucleotide sequence comprises all or part of SEQ ID NO. 2. 
     
     
         13 . Use in a medicament of a compound comprising HOXB4 protein to decrease survival of cancer cells in a mammal. 
     
     
         14 . The use of  claim 13 , wherein the mammal is a human. 
     
     
         15 . The use of  claim 13  or  claim 14 , wherein the HOXB4 protein comprises a polypeptide of all or part of SEQ ID NO. 1 
     
     
         16 . Use in a medicament of a transfection agent comprising a HOXB4 nucleotide sequence to decrease survival of cancer cells in a mammal. 
     
     
         17 . The use of  claim 16 , wherein the mammal is a human. 
     
     
         18 . The use of  claim 17  or  claim 18 , wherein the HOXB4 nucleotide sequence comprises a nucleotide sequence of all or part of SEQ ID NO. 2. 
     
     
         19 . A pharmaceutical composition for treatment of cancer comprising a polypeptide of all or part of SEQ ID NO. 1 and a pharmaceutically acceptable carrier. 
     
     
         20 . A pharmaceutical composition for treatment of cancer comprising a nucleotide sequence of all or part of SEQ ID NO. 2 and a pharmaceutically acceptable carrier. 
     
     
         21 . A method of treating a mammalian patient having a malignancy, said method comprising administering to the patient a pharmaceutical composition according to  claim 19  or  claim 20  in a therapeutically effective amount. 
     
     
         22 . The method according to  claim 21 , wherein the pharmaceutical composition is administered locally to a tumor site. 
     
     
         23 . The method according to  claim 21 , wherein the pharmaceutical composition is administered by direct injection to a tumor. 
     
     
         24 . The method according to  claim 21 , wherein the pharmaceutical composition is administered by intravenous injection. 
     
     
         25 . The method according to  claim 21 , wherein the administration is performed at two or more separate times.

Join the waitlist — get patent alerts

Track US2008269107A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.